Copyright
©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Characteristic | Follow up (wk) | Control group (n = 38) | TCM group (n = 40) | P value |
Urine protein (g/24 h) | 4 | 1.11 ± 1.54 | 0.73 ± 1.48 | 0.008 |
12 | 0.67 ± 0.91 | 0.34 ± 0.82 | 0.0159 | |
24 | 0.30 ± 0.29 | 0.09 ± 0.14 | < 0.0001 | |
Urine RBC count/HPF | 4 | 17.63 ± 15.48 | 9.02 ± 8.78 | 0.001 |
12 | 10.55 ± 9.73 | 4.35 ± 8.54 | 0.0007 | |
24 | 10.47 ± 8.43 | 2.82 ± 5.11 | < 0.0001 | |
Serum albumin (g/L) | 4 | 34.60 ± 6.57 | 36.36 ± 4.91 | 0.324 |
8 | 37.27 ± 6.64 | 39.35 ± 3.82 | 0.428 | |
12 | 39.65 ± 6.73 | 41.16 ± 3.99 | 0.701 | |
16 | 40.26 ± 6.45 | 41.17 ± 5.02 | 0.879 | |
20 | 41.50 ± 5.16 | 41.08 ± 7.00 | 0.821 | |
24 | 40.30 ± 6.28 | 41.15 ± 5.14 | 0.808 | |
Serum C3 (g/L) | 4 | 0.61 ± 0.14 | 0.53 ± 0.19 | 0.112 |
8 | 0.73 ± 0.16 | 0.69 ± 0.25 | 0.205 | |
12 | 0.80 ± 0.19 | 0.73 ± 0.0.21 | 0.143 | |
16 | 0.82 ± 0.15 | 0.77 ± 0.20 | 0.452 | |
20 | 0.82 ± 0.15 | 0.85 ± 0.14 | 0.874 | |
24 | 0.88 ± 0.17 | 0.86 ± 0.22 | 0.990 | |
Serum C4 (g/L) | 4 | 0.10 ± 0.04 | 0.08 ± 0.05 | 0.800 |
8 | 0.12 ± 0.05 | 0.11 ± 0.05 | 0.730 | |
12 | 0.14 ± 0.07 | 0.10 ± 0.05 | 0.122 | |
16 | 0.15 ± 0.06 | 0.13 ± 0.05 | 0.235 | |
20 | 0.16 ± 0.06 | 0.14 ± 0.06 | 0.874 | |
24 | 0.18 ± 0.07 | 0.18 ± 0.23 | 0.624 | |
SCR (μmol/L) | 4 | 44.75 ± 19.10 | 42.65 ± 12.86 | 0.768 |
8 | 44.18 ± 19.10 | 44.02 ± 13.08 | 0.794 | |
12 | 59.08 ± 76.32 | 45.17 ± 14.43 | 0.244 | |
16 | 46.53 ± 11.70 | 48.81 ± 14.68 | 0.922 | |
20 | 49.46 ± 12.47 | 49.38 ± 14.09 | 0.939 | |
24 | 50.11 ± 9.58 | 45.40 ± 10.32 | 0.060 | |
BUN (IU/mL) | 4 | 6.93 ± 2.60 | 6.08 ± 2.01 | 0.135 |
8 | 6.24 ± 3.13 | 5.46 ± 2.04 | 0.492 | |
12 | 5.20 ± 1.86 | 5.39 ± 1.61 | 0.654 | |
16 | 5.04 ± 1.38 | 5.04 ± 1.60 | 0.975 | |
20 | 4.93 ± 1.42 | 4.67 ± 1.43 | 0.469 | |
24 | 4.88 ± 1.24 | 4.34 ± 1.38 | 0.051 | |
Dosage of GCs | 0 | 55.05 ± 7.44 | 52.70 ± 10.94 | 0.683 |
4 | 52.94 ± 6.38 | 46.79 ± 12.72 | 0.098 | |
8 | 47.67 ± 6.44 | 40.78 ± 12.11 | 0.011 | |
12 | 43.58 ± 6.32 | 35.14 ± 12.77 | < 0.0001 | |
16 | 39.14 ± 5.38 | 30.62 ± 9.87 | 0.0001 | |
20 | 34.64 ± 5.04 | 25.74 ± 8.84 | 0.060 | |
24 | 31.44 ± 4.85 | 17.61 ± 7.45 | < 0.0001 | |
ds-DNA positive, n (%) | 24 | 10 (26.3) | 9 (22.5) | 0.694 |
SLEDAI | 4 | 11.00 ± 5.21 | 9.02 ± 4.02 | 0.073 |
12 | 7.16 ± 3.52 | 6.58 ± 3.64 | 0.625 | |
24 | 5.67 ± 4.27 | 5.12 ± 3.48 | 0.990 |
- Citation: Cao TT, Chen L, Zhen XF, Zhao GJ, Zhang HF, Hu Y. Dan Bai Xiao Formula combined with glucocorticoids and cyclophosphamide for pediatric lupus nephritis: A pilot prospective study. World J Clin Cases 2022; 10(31): 11391-11402
- URL: https://www.wjgnet.com/2307-8960/full/v10/i31/11391.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i31.11391